City page
Heidelberg biotech and pharma directory
Heidelberg is Germany's flagship biotech city — anchored by the German Cancer Research Center (DKFZ, the country's leading non-profit cancer institute), the European Molecular Biology Laboratory (EMBL Heidelberg), Heidelberg University, and the BioRN cluster. The commercial layer includes Hummingbird Diagnostics (microRNA), AGC Biologics manufacturing site, and dozens of biotech operators across the Rhine-Neckar region. Mainz nearby hosts BioNTech.
Where does this city read strongest?
Therapeutics (3), Research (2), and CDMO (2). Most visible records: VERAXA Biotech GmbH, Hummingbird Diagnostics, and TolerogenixX.
Which standards and public evidence are already visible?
GMP (2) and GLP (5). Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Heidelberg.
By category
Heidelberg by category
Jump into a category page filtered to this country only.
Full list
Heidelberg biotech and pharma directory
10 city records currently match the active filter.
Current review cycle
VERAXA Biotech GmbH
HeidelbergGermanyBiotech
Heidelberg antibody and antibody-drug conjugate platform company offering target-to-ADC discovery partnerships to oncology programs, with a proprietary high-throughput antibody screening engine.
- Lead
- Christoph AntzManaging Director and Chief Executive Officer
- Scale
- Research-stage discovery and partnership delivery
Current review cycle
Hummingbird Diagnostics
HeidelbergGermanyDiagnostics
Heidelberg molecular diagnostics company developing miRNA-based liquid-biopsy assays for neurological disease and oncology applications.
- Lead
- Tillman WeissChief Executive Officer
- Scale
- Diagnostics platform
Current review cycle
TolerogenixX
HeidelbergGermanyTherapeutics
Heidelberg cell-therapy company developing tolerogenic dendritic-cell approaches for autoimmune disease and transplant-related applications.
- Lead
- Matthias SchaierChief Executive Officer
- Scale
- Clinical-stage cell-therapy platform
Current review cycle
AGC Biologics Heidelberg
HeidelbergGermanyCDMO
Heidelberg biomanufacturing site within AGC Biologics, providing microbial, pDNA, and mRNA process development and GMP manufacturing services from Germany.
- Lead
- Patrik JonssonChief Executive Officer
- Scale
- Commercial and clinical manufacturing platform
Current review cycle
German Cancer Research Center
HeidelbergGermanyResearch
Heidelberg cancer-research flagship integrating oncologic discovery, prevention, translational programmes, and national research infrastructure.
- Lead
- Prof. Dr. Michael BaumannChairman and Scientific Director
- Scale
- Large national oncology-research centre
Current review cycle
BioRN Life Science Cluster
HeidelbergGermanyCluster
Rhine-Neckar life-science cluster platform connecting biotech companies, research institutions, investors, and translational programmes across Heidelberg.
- Lead
- Dr. Julia SchaftManaging Director
- Scale
- Rhine-Neckar cluster coordination hub
Current review cycle
EMBL Heidelberg
HeidelbergGermanyResearch
Heidelberg European molecular-biology site linking structural biology, genomics, data, and international training infrastructure into the wider cluster.
- Lead
- Jan KorbelInterim Head of Site, EMBL Heidelberg
- Scale
- European molecular-biology flagship site
Current review cycle
FyoniBio
HeidelbergGermanyCDMO
Berlin biologics-development and bioanalytical platform supporting cell-line development, CMC, and analytical packages for biopharma programmes.
- Lead
- Philippe UlsemerCo-Founder and Chief Executive Officer
- Scale
- Integrated biologics-development platform
Current review cycle
Heidelberg Pharma
HeidelbergGermanyTherapeutics
Ladenburg antibody-drug-conjugate platform focused on amanitin payload technology and oncology pipeline development.
- Lead
- Dr. Dongzhou Jeffery LiuChief Executive Officer
- Scale
- Clinical-stage ADC platform
Current review cycle
RHEACELL
HeidelbergGermanyTherapeutics
Heidelberg regenerative-medicine company focused on stromal-cell therapies and clinical-stage cell-based products.
- Lead
- Dr. Christoph GanssPhysician, Chief Executive Officer and Founder
- Scale
- Clinical-stage regenerative-medicine platform
FAQ
Frequently asked questions
- Why is Heidelberg important for biotech?
- Heidelberg hosts the German Cancer Research Center (DKFZ — Germany's top non-profit cancer institute), the European Molecular Biology Laboratory (EMBL), Heidelberg University, and the BioRN cluster connecting industry to research. The Rhine-Neckar region around Heidelberg-Mannheim-Mainz is one of Europe's densest biotech corridors.
- What is the BioRN cluster?
- BioRN is the regional biotech cluster organization for the Rhine-Neckar metropolitan region, connecting Heidelberg, Mannheim, Ludwigshafen, and surrounding companies. It coordinates between industry, research institutes (DKFZ, EMBL, Heidelberg University), and policy makers. Membership signals integration into one of Germany's most active biotech ecosystems.
- What sectors are strongest in Heidelberg biotech?
- Heidelberg is strongest in oncology research and therapeutics (DKFZ-driven), molecular biology (EMBL ecosystem), microRNA diagnostics (Hummingbird), biologics manufacturing (AGC Biologics), and translational research from German non-profit institutes into commercial biotech. Mainz nearby anchors mRNA (BioNTech).
Related briefs
Briefs that mention Heidelberg
European mRNA & Immunotherapy Supply Chain 2026
Where the European mRNA, vaccine, and immunotherapy supply chain actually sits in 2026 — BioNTech, CureVac, IDT Biologika, AGC Biologics, BioSpring, Bachem, plus the Nordic vaccine layer — and how the pieces fit.
Open briefViral Vector CDMO Europe 2026: AAV, Adenovirus, Lentivirus
Where to manufacture viral vectors in Europe in 2026 — FinVector, Kuopio Center for Gene and Cell Therapy, 3PBIOVIAN, Fuse Vectors, IDT Biologika — and how the European viral vector CDMO layer is structured.
Open briefGerman Biotech & Pharma Landscape 2026: Heidelberg, Berlin, Mainz
A practical map of the German biotech and pharma landscape in 2026 — 57 operators across Heidelberg, Berlin, Mainz, Hamburg, Munich, and smaller sites, organised by what they actually do and how the pieces connect.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.